Loading
Nanjing Vishee Medical Technology Co., Ltd Stock: price and insider trades · China
伟思医疗
No insider purchase over the last 90 days. The latest was filed 17 Jul 2026.
Nanjing Vishee Medical Technology Co., Ltd: what insiders have been doing
This page follows insider dealings at Nanjing Vishee Medical Technology Co., Ltd as filed with SSE / SZSE (CSRC), a company from the Health Care sector. In the past year (18 October 2025 to 18 October 2026), 3 filings came from 1 insider.
Both sides are active: 2 purchases worth €41k and 1 sale worth €41k, from 1 insider and 1 insider respectively. Netting one side against the other leaves €101 of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. At €41k, the sale published on 5 January 2026 by 高飞 is the largest of the period.
The latest purchase dates back some time: it was published 93 days ago, on 17 July 2026. Half of the filings or more reach the SSE / SZSE (CSRC) feed on the day of the trade. The shorter that gap, the sooner other investors can see what insiders have done.
Across the 515 companies tracked on its exchange, the median is 2 filings; at 3 filings, this issuer sits above that mark. The full history, which starts in 2023, counts 3 purchases against 7 sales.
In the same sector, recent insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. also feature in our signals. This summary is built from SSE / SZSE (CSRC) disclosures alone and does not predict where the share price will go.
Insider Decl.
10
Thresholds
n/a
Buy Volume
€50,463
3 ops. · all time
Sell Volume
€254,456
7 ops. · all time
Who traded when
BuySale高飞3 buys1 sale
仇凯2 sales
陈莉莉1 sale
Since the insiders bought
- -20.6%Entry CN¥49.85 · Close 14 Oct 2026 CN¥39.60
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 6,283 of 24,166 companies
63.5
score / 100
Value43
Quality85
FCF yld1.6%
Earn yld3.7%
EV/EBITDA20.2x
ROE10%
Gross mgn66%
Net mgn30%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CN¥40.85
Analyst consensus
1 analysts1.00/5
CN¥63.00Target CN¥63.00(+54%)CN¥63.00
Income statement
RevenueCN¥462.7M
Gross profitCN¥306.3M66% margin
EBITDACN¥183.7M40% margin
Net incomeCN¥138.1M35.3% margin
Valuation
PER (trailing)23.1x
PER (forward)22.8x
P/Book2.3x
Beta0.46
Balance sheet & cash
Market capCN¥3.9B
Total debtCN¥1.1M
Free Cash FlowCN¥58.6M
Debt / Equity0%
Profitability & ownership
ROE10.2%
ROA4.8%
% insiders65.4%
% institutions2.2%
Last declaration on 17 July 2026
Declarations10 total
10 of 10 declarations
About Nanjing Vishee Medical Technology Co., Ltd
伟思医疗 is a company operating in the healthcare and pharmaceutical sector, listed on the Shanghai Stock Exchange. It focuses on the development and commercialization of innovative medical solutions.
